Please assess the completion status of the following clinical trial:

Trial Title: Desvenlafaxine in Opioid-Dependent Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV-TR criteria for opioid dependence;~* Subject is on methadone treatment in the substitution program for at least 4 weeks;~* Subject is aged between 18 and 65 years old;~* subject meets the DSM-V TR criteria for major depressive episode, according to the study psychiatrist and confirmed by the Mini International Neuropsychiatric Interview (MINI);~* Subject reports a score of 20 or higher on the MADRS;~* Subject is eligible for and consents to the study;~* subject is able to give valid, informed consent;~* subject is able to speak and read French or English (grade-nine level of language required)~Exclusion Criteria:~* Unstable medical illness, defined as any medical illness which has not been well-controlled with standard-of-care medications;~* Severe psychiatric condition (e.g., current acute psychosis, past or current hypomania/mania) based on the MINI;~* Pregnancy or breastfeeding;~* Inability to use a medically acceptable form of contraception throughout the study duration. A medically acceptable form of contraception is either: (1) contraceptive pill or intrauterine device or depot hormonal preparation (ring, injection, implant); and/or (2) a barrier method of contraception such as diaphragm, sponge with spermicide or condom;~* Subject currently takes another antidepressant;~* Treatment with Desvenlafaxine at any time in the past;~* Known hypersensitivity to venlafaxine;~* Subject is undergoing psychotherapies for current depression (support therapy or counseling are allowed);~* Subject failed to respond to two or more Health-Canada-approved antidepressants during current episode;~* Unstable Axis-II personality disorder or other Axis-II disorder which has been the primary focus of treatment in the past 3 months, as ascertained by a study psychiatrists;~* Medical diagnosis of kidney and/or liver failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Desvenlafaxine (Type: OTHER): * Open-label pilot study~* Desvenlafaxine will be administered during 56 consecutive days~* Desvenlafaxine will be administered in the morning at a 50 mg dose during weeks 1 and 2, and at 50-100 mg doses (based on the study psychiatrist's judgment) during the 6 following weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).